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OBJECTIVE—To assess the effect of intraday glucose variability (GV) on cardiovascular out-
comes in a reanalysis of Hyperglycemia and Its Effect After Acute Myocardial Infarction on
Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) study data.
RESEARCH DESIGN AND METHODS—Type 2 diabetic patients after acute myocar-
dial infarction were randomized to an insulin treatment strategy targeting postprandial
(PRANDIAL; n = 557) or fasting/interprandial (BASAL; n = 558) hyperglycemia. GV was calcu-
lated as mean amplitude of glycemic excursions (MAGE), mean absolute glucose (MAG) change,
and SD.
RESULTS—ThePRANDIALstrategyresultedinan18%lowerMAGthanBASAL(mean[SEM]
difference 0.09 [0.04] mmol/L/h, P = 0.02). In addition, MAGE and SD were lower in the
PRANDIAL group, however, not signiﬁcantly. HbA1c levels and cardiovascular event rates were
comparable between groups.
CONCLUSIONS—APRANDIALstrategydemonstratedlowerintradayGV vs.aBASALstrat-
egy with similar overall glycemic control but did not result in a reduction in cardiovascular
outcomes. This does not support the hypothesis that targeting GV would be beneﬁcial in re-
ducing subsequent secondary cardiovascular events.
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hort-termvariationinbloodglucose
(BG) levels is a daily challenge for
patients with diabetes. It confers a
possible increased risk for hypoglycemia,
and it has been suggested that glucose
variability (GV) is related to cardiovascu-
lar risk (1–3 ) .H o w e v e r ,r e a n a l y s i so ft h e
DiabetesControlandComplicationsTrial
(DCCT) and DCCT/Epidemiology of Di-
abetes Interventions and Complications
(EDIC) dataset examining the predictive
value of GV on microvascular and neuro-
logiccomplicationsdidnotshowaneffect
ofGVindependentfrommeanglucoseand
HbA1c (4–6), and randomized controlled
trials (RCTs) speciﬁcally targeting GV are
lacking (7,8).
To assess the effect of intraday GV on
cardiovascular outcomes we re-examined
data from Hyperglycemia and Its Effect
AfterAcuteMyocardial InfarctiononCar-
diovascular Outcomes in Patients With
Type 2 Diabetes Mellitus study (HEART2D;
clinical trial reg. no. NCT00191282,
clinicaltrials.gov) (9).
RESEARCH DESIGN AND
METHODS—The HEART2D study in-
cluded1,115type2diabeticpatientswho
had had a recent myocardial infarction;
patientswell-controlledwithdietortreated
with intensive insulin therapy were ex-
cluded. It was designed to investigate
possible differences between two insulin
treatment strategies on time until ﬁrst
combined cardiovascular event (a com-
posite of cardiovascular death, nonfatal
myocardial infarction, nonfatal stroke,
coronary revascularization, or hospitaliza-
tion for acute coronary syndrome) (9).
Within 21 days after admission for acute
myocardial infarction, patients were ran-
domized to one of two insulin treatment
strategies: one targeted postprandial hy-
perglycemia with thrice-daily premeal in-
sulin lispro (PRANDIAL; n = 557), and
the other targeted fasting/interprandial
hyperglycemia with once-daily insulin
glargine or twice-daily NPH (BASAL; n =
558). The study succeeded in achieving
similar HbA1c levels in both strategies,
which allowed the authors to look at
effects of targeting postprandial glucose
values independent fromglycemiccontrol.
There was no signiﬁcant difference be-
tweengroupsintimetoﬁrstcombinedcar-
diovascular event (hazard ratio 0.98 [95%
CI 0.8–1.21]). Though the PRANDIAL
group achieved signiﬁcantly lower mean
postprandial blood glucose values, the
between-group differencewas lessthanex-
pected. The trial was halted early due to
futility with a lower than expected overall
number of cardiovascular events. We eval-
uated the effect of glycemic variability to
helpfurthertheinterpretationofHEART2D
results.
In the present analysis we calculated
mean GV in both strategies from 7-point
self-measuredBGproﬁlescollectedpriorto
study visits during the study period, ob-
tainedover24hfrombreakfasttobreakfast
the next morning.Thisadds to the original
analysissincepostprandialexcursionscon-
tribute to GV, but GV encompasses more
than postprandial excursions alone. Be-
cause no gold standard for quantifying
GV exists (7), we calculated mean absolute
glucose (MAG) change, meanamplitude of
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MAG is the summated change in glucose
per unit of time (MAG = |DGlucose|/
DTime) (Fig. 1), which showed in the in-
tensivecareunitastrongerassociationwith
mortalitythanSD(10).Thisistheﬁrsttime
MAG is used in a diabetic population.
MAGE is the average of all BG increases
or decreases that are .1 SD of all BG mea-
sures (11). Differences between regimens
and those experiencing versus those not
experiencing a cardiovascular event were
assessed using a pattern mixed-model
repeated-measurementanalysis.Themodel
includedstrategy,baselineGV,randomiza-
tion factors, and an additional factor for
study duration (deﬁned as #30, .30 and
#42, and .42 months) (9).
RESULTS—The original HEART2D
study analysis showed that HbA1c did
not differ between groups during the
study (mean [SEM] PRANDIAL 7.7 [0.1]
%,BASAL7.8[0.1]%,P=0.4).Wefound
that the PRANDIAL strategy resulted in
as i g n i ﬁcantly lower MAG compared
with the BASAL strategy (mean [SEM]
PRANDIAL 0.40 [0.03]mmol/L/h, BASAL
0.49 [0.02] mmol/L/h, difference 0.09
[0.04] mmol/L/h, P = 0.02). Also MAGE
and SD were lower in the PRANDIAL
group, however, not signiﬁcantly (MAGE
PRANDIAL 3.14 [0.22] mmol/L, BASAL
3.32 [0.17] mmol/L, difference 0.18
[0.27] mmol/L, P = 0.50; SD PRANDIAL
1.42 [0.09] mmol/L, BASAL 1.58 [0.07]
mmol/L, difference 0.16 [0.11] mmol/L,
P=0.15).Additionally,takingthetworan-
domization groups together, there was no
differenceinGVbetweenthoseexperiencing
versus those not experiencing a cardiovas-
cular event (mean [SEM] MAG 0.47 [0.03]
mmol/L/h vs. 0.44 [0.02] mmol/L/h, P =
0.57; MAGE 3.35 [0.23] mmol/L vs. 3.16
[0.16] mmol/L, P = 0.49; SD 1.56 [0.10]
mmol/L vs. 1.48 [0.07] mmol/L, P =0 . 5 2 ) .
CONCLUSIONS—We found that in
type 2 diabetic patients after acute myo-
cardial infarction an insulin regimen
targeting postprandial hyperglycemia
lowered intraday GV compared with a
basal insulin strategy, with similar overall
glycemic control. However, GV decreases
shown in the PRANDIAL strategy did not
translate into a reduction in cardiovascu-
lar outcomes compar e dw i t ht r e a t m e n t
with BASAL strategy.
Itmight be possible that these negative
results are explained by the patient group
studied, i.e., type 2 diabetic patients
with advanced atherosclerosis. Another
possibility is that patients with diabetes,
in contrast with critically ill patients with-
outpreviouslydiagnoseddiabetes(10),are
not affected by GV because of the ability of
cells to adapt to the harmful effects of
changing ambient glucose.
A strong point of the current study is
theassessmentofGVbyMAG.MAGtakes
Figure 1—Two ﬁctitious patients with identical mean glucose, SD, and MAGE, but different
patterns of variability expressed by MAG change.
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Glycemic variability and reanalysis of HEART2DGV into account to its fullest extent as
opposedtoMAGE,whichneglectsglycemic
swings smaller than 1 SD and assesses
only the increases or decreases of the
glucose proﬁle (11). Furthermore, MAG
calculates glucose change over time,
whereas SD does not take time into ac-
count (Fig. 1).
In conclusion, the results of the pres-
ent analysis showed that targeting post-
prandial glucose decreased intraday GV
by 18% without a corresponding reduc-
tion in subsequent secondary cardiovas-
cular events at least in this population.
Further studies looking at different
groupsofpatientsareneededtoinvestigate
whether reducing GV will reduce cardio-
vascular risk independently from HbA1c.
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